CA3105857A1 — Dosage regimen of an s1p receptor agonist

USPTO Abstract

Disclosed are kits for treating multiple sclerosis comprising units of medication of 1-{4-(1-(4- cyclohexyl-3-trifluoromethylbenzyloxyimino)-ethyl]-2-ethyl-benzylyazetidine-3- carboxylic acid The units of medication may each contain 0.25 mg of Compound A and be for administration to a patient during an initial period of treatment and be a dose strength lower than a standard daily dosage of Compound A. Also disclosed are uses of Compound A for treating multiple sclerosis in a patient where Compound A is for administration via one or more units of medication, each unit of medication containing, e.g., 0.25 mg of Compound A. In the use, Compound A may be for administration during an initial period of treatment of 5 days with the daily dosage during the initial period of treatment being 0.25 mg (day 1), 0.25 mg (day 2), 0.5 mg (day 3), 0.75 mg (day 4), and 1.25 mg (day 5).